TheGreat IndianHistory

#EHA2023 - #Vertex & CRISPR Therapeutics presented positive data of cell therapy in beta-#thalassemia and #sicklecelldisease #patients ipharmacenter.com/post/annual-eu… #Pharma #pharmaceutical #healthcare #globalhealth #Patientcare #news #media #medicine #digitalhealth #PublicHealth #EHA23

#Janssen presented the overall survival benefit of #Balversa versus #chemotherapy in #urothelialcarcinoma #patients. ipharmacenter.com/post/asco-2023… #pharma #pharmaceutical #media #ASCO2023 #Oncology #Cancer #medicine #medtwitter #meded #Science #Research #Technology #News #ASCO23 #ASCO

#Gilead presented real-world evidence data of #Tecartus. ipharmacenter.com/post/asco-2023… #pharma #pharmaceutical #media #ASCO2023 #Mesothelioma #ASCO23 #Cancer #medicine #medtwitter #meded #Science #Research #Technology #News #mantlecelllymphoma #lymphoma #bloodcancer #bloodmatters

#UCB's #bimekizumab demonstrated long-term benefit in #psoriaticarthritis & #axialspondyloarthritis patientshttps://www.ipharmacenter.com/post/eular-2023-news-updates #Pharma #pharmaceutical #PublicHealth #arthritis #EULAR2023 #EULAR23 #rheumatology #immunology #dermatology #news

#Novartis presented positive Phase 3 trial results in early #breastcancer patients; #Lilly's CDK4/6 inhibitor now faces competition. ipharmacenter.com/post/asco-2023… #news #Media #ASCO23 #ASCO2023 #ASCOUpdates #ASCONews #pharma #pharmaceutical #cancer #oncology #CancerResearch #GlobalNews

#Merck presented new data on #Keytruda, demonstrating improvements in early-stage perioperative #NSCLC patients. ipharmacenter.com/post/asco-2023… #news #Media #ASCO23 #ASCO2023 #ASCOUpdates #ASCONews #pharma #pharmaceutical #cancer #oncology #CancerResearch #GlobalNews #lungcancer

#Regeneron presented Phase 2 data of heavily pre-treated patients with relapsed/refractory #multiplemyeloma ipharmacenter.com/post/asco-2023… #news #media #pharma #pharmaceutical #ASCO23 #ASCO2023 #Oncology #oncologist #bloodcancer #bloodmatters #news #media #healthcare #globalhealth

#Merck and #Eisai presented the long-term benefits of the #Keytruda and #Lenvima combination in #renalcellcarcinoma #patients. ipharmacenter.com/post/asco-2023… #news #media #pharma #pharmaceutical #ASCO23 #ASCO2023 #Oncology #oncologist #lungcancer #bloodmatters #news #media #healthcare

#BMS presented data on #Breyanzi in patients with relapsed/refractory #chroniclymphocyticleukemia. ipharmacenter.com/post/asco-2023… #news #media #pharma #pharmaceutical #ASCO23 #ASCO2023 #Oncology #oncologist #lungcancer #bloodmatters #news #media #healthcare #leukemia #CART #celltherapy

#Janssen at #ASCO23: #Rybrevant and #lazertinib combination therapy shows promising long-term results in EGFR-mutated #NSCLC ipharmacenter.com/post/asco-2023… #pharma #pharmaceutical #ASCO2023 #lungcancer #MedTwitter #Oncotwitter #medicine #medtwitter #Science #Research #Technology #News

The median progression-free survival was #zimberelimab monotherapy: 5.4 months #omvanalimab plus zimberelimab: 9.3 months #etrumadenant, #domvanalimab, zimberelimab triple therapy: 9.9 months ipharmacenter.com/post/asco-2023… #ASCO2023 #ASCO23 #MedTwitter #Oncology #CancerResearch #Science

#Janssen presented long-term data of its bispecific antibody #talquetamab in patients with #multiplemyeloma ipharmacenter.com/post/asco-2023… #pharma #pharmaceutical #media #ASCO2023 #lungcancer #Oncology #Cancer #medicine #medtwitter #meded #Science #Research #Technology #News

#Gilead and #Arcus report positive results for domvanalimab in the #NSCLC trial ipharmacenter.com/post/asco-2023… #news #media #ASCO2023 #ASCO23 #pharma #pharmaceutical #healthcare #OncoAlertTopTweet #OncoTwitter #MedicalTwitter #globalhealth #cancer #lungcancer #oncologist #oncology #ASCO

#Moderna and #Merck presented data of neoantigen therapy V940 and #Keytruda in high-risk #melanoma patients. ipharmacenter.com/post/asco-2023… #ASCO23 #ASCO2023 #pharma #pharmaceutical #globalpharma #MedTwitter #OncoTwitter #Science #Medicine #healthcare #conferences #globalhealth

#Merck and the #Canadian #Cancer Trials Group presented positive data on #Keytruda in #mesothelioma patients ipharmacenter.com/post/asco-2023… #pharma #pharmaceutical #media #ASCO2023 #Mesothelioma #Oncology #Cancer #medicine #medtwitter #meded #Science #Research #Technology #News

#Gilead presented #Trodelvy OS data in HR+/HER2-metastatic #breastcancer. ipharmacenter.com/post/asco-2023… #pharma #pharmaceutical #media #ASCO2023 #Mesothelioma #Oncology #Cancer #medicine #medtwitter #news #meded #Science #Research #Technology #News #WomenHealth #GlobalHealth

#AbbVie moves #Rinvoq into Phase 3 trials for #SystemicLupusErythematosus. ipharmacenter.com/post/systemic-… #Pharma #pharmaceutical #healthcare #globalhealth #Patientcare #news #media #medicine #digitalhealth #PublicHealth #lupus #immunology

#Indonesia #healthcare system: The life expectancy was 63 years in 1990 and increased to 71 years in 2012. Infant mortality was reduced ipharmacenter.com/post/indonesia… #Pharma #pharmaceutical #healthcare #globalhealth #Patientcare #news #media #medicine #digitalhealth #PublicHealth

#China #healthcare - In 2016, China government planned to merge Urban-Rural Basic Medical Insurance & the Newly Cooperative Medical Scheme. ipharmacenter.com/post/healthcar… #Pharma #pharmaceutical #healthcare #globalhealth #Patientcare #news #media #medicine #digitalhealth #PublicHealth

#Kisqali met the primary endpoint in the NATALEE trial, demonstrating benefit in early #breastcancer patients. ipharmacenter.com/post/breast-ca… #Pharma #pharmaceutical #healthcare #globalhealth #Patientcare #news #media #medicine #digitalhealth #PublicHealth #Cancer #Oncologist #Oncology